{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:25:28Z","timestamp":1792027528175,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>LVAD utility in heart failure patients is growing. Despite advancement in technology rates of LVAD- related infections remain high limiting outcomes. We aimed to assess the effectiveness and safety of oritavancin for LVAD-related Gram-positive infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study evaluating adult LVAD patients who received\u2009\u2265\u20091 oritavancin dose for treatment of Gram-positive LVAD-related infection between September 2022 and December 2024. Oritavancin was given at the end of shortened standard antibiotic therapy. The primary endpoint was 90-day clinical and microbiological cure of the primary or relapsing infection within 90 days from the first oritavancin dose. Secondary endpoints were adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, nine patients were included. All were male, mean age was 53\u2009\u00b1\u20099 years. In total they experienced 10 LVAD- related episodes. Most episodes (80%) were deep drive-line infections. The organism most commonly responsible for infection was\n                      <jats:italic>Staphyloccocus aureus<\/jats:italic>\n                      . Oritavancin was administered after a median time of 31\u2009\u00b1\u200913 days of standard antibiotic therapy. In total 18 doses of oritavancin were administered with a median of 2 per case separated on average by 20\u2009\u00b1\u20094 days. Primary endpoint was achieved in 90% of cases, shortening therapy by a median time of 24 days. Serious adverse events occurred in two of 9 patients: delirium and shivers, both with transient increase of inflammatory markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oritavancin has a potential to shorten inhospital therapy and improve outcomes in LVAD-related Gram-positive infections in advanced heart failure patients. The study is the first to report delirium and transient increase in inflammatory biomarkes as side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11692-x","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:43Z","timestamp":1761042463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes"],"prefix":"10.1186","volume":"25","author":[{"given":"Marta","family":"Za\u0142\u0119ska-Koci\u0119cka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Mielczarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"G\u00f3ral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Marcinkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Byczkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Zatorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Cie\u015blik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Paszy\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Tomaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ko\u0142sut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"J\u00f3\u017awik-Plebanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Kuriata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Szyma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Leszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"11692_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.athoracsur.2023.11.004","volume":"117","author":"UP Jorde","year":"2024","unstructured":"Jorde UP, Saeed O, Koehl D, et al. The society of thoracic surgeons intermacs 2023 annual report: focus on magnetically levitated devices. Ann Thorac Surg. 2024;117:33\u201344.","journal-title":"Ann Thorac Surg"},{"key":"11692_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.healun.2017.06.007","volume":"36","author":"S Kusne","year":"2017","unstructured":"Kusne S, Mooney M, Danziger-Isakov L, et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Heart Lung Transplant. 2017;36:1137\u201353.","journal-title":"J Heart Lung Transplant"},{"key":"11692_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13019-021-01589-6","volume":"16","author":"A Juraszek","year":"2021","unstructured":"Juraszek A, Sm\u00f3lski M, Ko\u0142sut P, et al. Prevalence and management of driveline infections in mechanical circulatory support - a single center analysis. J Cardiothorac Surg. 2021;16:216.","journal-title":"J Cardiothorac Surg"},{"key":"11692_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2022.12.004","volume":"42","author":"D Saeed","year":"2023","unstructured":"Saeed D, Feldman D, Banayosy AE, et al. The 2023 international society for heart and lung transplantation guidelines for mechanical circulatory support: A 10- year update. J Heart Lung Transplantation. 2023;42:e1\u2013222.","journal-title":"J Heart Lung Transplantation"},{"key":"11692_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106763","volume":"61","author":"S-S Jean","year":"2023","unstructured":"Jean S-S, Liu I-M, Hsieh P-C, et al. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria. Int J Antimicrob Agents. 2023;61:106763.","journal-title":"Int J Antimicrob Agents"},{"key":"11692_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2018.01.029","volume":"91","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Sader HS, Flamm RK, et al. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY antimicrobial surveillance program for 2010\u20132014. Diagn Microbiol Infect Dis. 2018;91:199\u2013204.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"11692_CR7","doi-asserted-by":"publisher","first-page":"e01667","DOI":"10.1128\/AAC.01667-21","volume":"66","author":"CG Carvalhaes","year":"2022","unstructured":"Carvalhaes CG, Sader HS, Streit JM, et al. Activity of Oritavancin against Gram-positive pathogens causing bloodstream infections in the united States over 10 years: focus on Drug-resistant enterococcal subsets (2010\u20132019). Antimicrob Agents Chemother. 2022;66:e01667-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"11692_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.healun.2020.03.010","volume":"39","author":"RL Kormos","year":"2020","unstructured":"Kormos RL, Antonides CFJ, Goldstein DJ, et al. Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the mechanical circulatory support academic research consortium. J Heart Lung Transplant. 2020;39:735\u201350.","journal-title":"J Heart Lung Transplant"},{"key":"11692_CR9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1128\/AAC.00766-08","volume":"53","author":"A Belley","year":"2009","unstructured":"Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53:918\u201325.","journal-title":"Antimicrob Agents Chemother"},{"key":"11692_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/QCO.0000000000000999","volume":"37","author":"C Eckmann","year":"2024","unstructured":"Eckmann C, Sunderk\u00f6tter C, Becker K, et al. Left ventricular assist device-associated driveline infections as a specific form of complicated skin and soft tissue infection\/acute bacterial skin and skin structure infection \u2013 issues and therapeutic options. Curr Opin Infect Dis. 2024;37:95.","journal-title":"Curr Opin Infect Dis"},{"key":"11692_CR11","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180\u201390.","journal-title":"N Engl J Med"},{"key":"11692_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60:254\u201362.","journal-title":"Clin Infect Dis"},{"key":"11692_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","volume":"41","author":"M Poliseno","year":"2021","unstructured":"Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different Gram-positive bacterial infections. Clin Drug Investig. 2021;41:437\u201348.","journal-title":"Clin Drug Investig"},{"key":"11692_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14068","volume":"25","author":"A-R Mansoor","year":"2023","unstructured":"Mansoor A-R, Krekel T, Cabrera NL. Experience with Dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections. Transplant Infect Dis. 2023;25:e14068.","journal-title":"Transplant Infect Dis"},{"key":"11692_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/CCM.0000000000002208","volume":"45","author":"VD Dinglas","year":"2017","unstructured":"Dinglas VD, Aronson Friedman L, Colantuoni E, et al. Muscle weakness and 5-year survival in acute respiratory distress syndrome survivors. Crit Care Med. 2017;45:446\u201353.","journal-title":"Crit Care Med"},{"key":"11692_CR16","doi-asserted-by":"publisher","first-page":"e01968","DOI":"10.1128\/AAC.01968-16","volume":"61","author":"A Belley","year":"2017","unstructured":"Belley A, Robson R, Francis JL, et al. Effects of oritavancin on coagulation tests in the clinical laboratory. Antimicrob Agents Chemother. 2017;61:e01968-16.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11692-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:23:54Z","timestamp":1781612634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11692-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11692"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11692-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6558671\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to retrospective nature of the study informed patient consent was waived by Local Ethics Comity of Stefan Cardinal Wyszynski National Institute of Cardiology in Warsaw, Poland. The study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MZK and SM honorary lectures form Berlin Chemie.\u00a0All other authors do not have any competing interest","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1358"}}